| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyotrophic Lateral Sclerosis | 47 | 2020 | 1431 | 3.190 |
Why?
|
| Data Interpretation, Statistical | 16 | 2018 | 2685 | 1.310 |
Why?
|
| Clinical Trials as Topic | 23 | 2019 | 7935 | 1.110 |
Why?
|
| Research Design | 18 | 2022 | 6056 | 1.080 |
Why?
|
| Survival Analysis | 21 | 2018 | 10127 | 1.080 |
Why?
|
| Tobacco Use Disorder | 5 | 2022 | 695 | 1.060 |
Why?
|
| Air Ambulances | 2 | 2023 | 89 | 1.060 |
Why?
|
| Sample Size | 7 | 2022 | 832 | 1.020 |
Why?
|
| Control Groups | 2 | 2019 | 105 | 0.960 |
Why?
|
| Clinical Trials, Phase II as Topic | 5 | 2019 | 626 | 0.950 |
Why?
|
| Biometry | 8 | 2015 | 560 | 0.930 |
Why?
|
| Randomized Controlled Trials as Topic | 15 | 2022 | 10094 | 0.910 |
Why?
|
| Disease Progression | 20 | 2020 | 13303 | 0.860 |
Why?
|
| Models, Statistical | 12 | 2018 | 5027 | 0.820 |
Why?
|
| Tobacco Use Cessation | 1 | 2022 | 92 | 0.770 |
Why?
|
| Smoking Cessation | 7 | 2022 | 2069 | 0.730 |
Why?
|
| Hydroxylamines | 2 | 2018 | 39 | 0.700 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2013 | 848 | 0.670 |
Why?
|
| Neuroprotective Agents | 4 | 2020 | 950 | 0.580 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 6781 | 0.560 |
Why?
|
| Positive-Pressure Respiration | 5 | 2015 | 628 | 0.500 |
Why?
|
| Markov Chains | 3 | 2015 | 958 | 0.500 |
Why?
|
| Survival Rate | 14 | 2019 | 12632 | 0.480 |
Why?
|
| Nitriles | 3 | 2016 | 946 | 0.460 |
Why?
|
| Double-Blind Method | 39 | 2021 | 12208 | 0.460 |
Why?
|
| Ceftriaxone | 4 | 2016 | 170 | 0.450 |
Why?
|
| Triazoles | 3 | 2016 | 902 | 0.440 |
Why?
|
| Testosterone | 16 | 2020 | 2440 | 0.440 |
Why?
|
| Phenylbutyrates | 3 | 2020 | 72 | 0.440 |
Why?
|
| Bayes Theorem | 4 | 2019 | 2272 | 0.420 |
Why?
|
| Anorexia Nervosa | 6 | 2021 | 1370 | 0.420 |
Why?
|
| Aromatase Inhibitors | 3 | 2016 | 509 | 0.410 |
Why?
|
| Nicotinic Agonists | 5 | 2017 | 264 | 0.410 |
Why?
|
| Schizophrenia | 13 | 2017 | 6838 | 0.400 |
Why?
|
| Acquired Immunodeficiency Syndrome | 8 | 2003 | 2204 | 0.390 |
Why?
|
| Humans | 227 | 2024 | 746044 | 0.370 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 3784 | 0.370 |
Why?
|
| Taurochenodeoxycholic Acid | 2 | 2020 | 35 | 0.370 |
Why?
|
| Medical Futility | 3 | 2010 | 123 | 0.350 |
Why?
|
| Enteral Nutrition | 2 | 2017 | 769 | 0.350 |
Why?
|
| Cycloserine | 3 | 2008 | 113 | 0.350 |
Why?
|
| Extracellular Fluid | 1 | 2011 | 165 | 0.340 |
Why?
|
| Neurodegenerative Diseases | 1 | 2019 | 1059 | 0.340 |
Why?
|
| Insulin-Like Growth Factor I | 9 | 2021 | 1905 | 0.340 |
Why?
|
| Human Growth Hormone | 6 | 2013 | 632 | 0.340 |
Why?
|
| Bipolar Disorder | 6 | 2017 | 5051 | 0.330 |
Why?
|
| Fructose | 4 | 2008 | 275 | 0.330 |
Why?
|
| Treatment Outcome | 44 | 2021 | 63661 | 0.320 |
Why?
|
| Antipsychotic Agents | 10 | 2016 | 3053 | 0.320 |
Why?
|
| Monitoring, Ambulatory | 2 | 2011 | 347 | 0.320 |
Why?
|
| Bone Density | 12 | 2021 | 3510 | 0.300 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2022 | 3331 | 0.290 |
Why?
|
| Proportional Hazards Models | 11 | 2016 | 12273 | 0.290 |
Why?
|
| Adult | 120 | 2022 | 214958 | 0.280 |
Why?
|
| Computer Simulation | 9 | 2018 | 6146 | 0.270 |
Why?
|
| Creatine | 4 | 2019 | 414 | 0.270 |
Why?
|
| Aircraft | 2 | 2023 | 125 | 0.270 |
Why?
|
| Middle Aged | 112 | 2020 | 214412 | 0.270 |
Why?
|
| Lithium | 3 | 2016 | 597 | 0.270 |
Why?
|
| Isometric Contraction | 3 | 2004 | 140 | 0.270 |
Why?
|
| Marijuana Smoking | 2 | 2019 | 254 | 0.260 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2779 | 0.260 |
Why?
|
| Tidal Volume | 3 | 2019 | 482 | 0.260 |
Why?
|
| Intensive Care Units | 5 | 2019 | 3670 | 0.260 |
Why?
|
| Maximal Voluntary Ventilation | 1 | 2004 | 14 | 0.250 |
Why?
|
| Female | 139 | 2022 | 382109 | 0.250 |
Why?
|
| Wounds and Injuries | 2 | 2015 | 2409 | 0.240 |
Why?
|
| Parkinson Disease | 1 | 2019 | 2815 | 0.240 |
Why?
|
| Superoxide Dismutase | 4 | 2013 | 586 | 0.240 |
Why?
|
| Longitudinal Studies | 11 | 2021 | 14113 | 0.240 |
Why?
|
| Gonadotropin-Releasing Hormone | 13 | 2003 | 1158 | 0.240 |
Why?
|
| Severity of Illness Index | 15 | 2020 | 15537 | 0.230 |
Why?
|
| Cannabis | 2 | 2022 | 434 | 0.230 |
Why?
|
| Muscle Strength | 5 | 2019 | 599 | 0.230 |
Why?
|
| Algorithms | 9 | 2015 | 13796 | 0.230 |
Why?
|
| Male | 130 | 2020 | 351093 | 0.220 |
Why?
|
| Gene Expression Profiling | 4 | 2024 | 9310 | 0.220 |
Why?
|
| Benzothiazoles | 2 | 2016 | 244 | 0.220 |
Why?
|
| Data Collection | 3 | 2009 | 3287 | 0.220 |
Why?
|
| Body Composition | 13 | 2013 | 2381 | 0.210 |
Why?
|
| Luteinizing Hormone | 10 | 1999 | 826 | 0.210 |
Why?
|
| Emergency Medical Services | 2 | 2023 | 1886 | 0.200 |
Why?
|
| Riluzole | 3 | 2011 | 58 | 0.200 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 146 | 0.200 |
Why?
|
| Quinoxalines | 2 | 2014 | 286 | 0.200 |
Why?
|
| Benzazepines | 2 | 2014 | 312 | 0.190 |
Why?
|
| Endpoint Determination | 2 | 2018 | 586 | 0.190 |
Why?
|
| Chest Pain | 3 | 2013 | 1093 | 0.190 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2021 | 1207 | 0.190 |
Why?
|
| Follicle Stimulating Hormone | 10 | 1997 | 724 | 0.190 |
Why?
|
| Glucose | 3 | 2011 | 4302 | 0.190 |
Why?
|
| Time Factors | 30 | 2019 | 39587 | 0.190 |
Why?
|
| Burns | 7 | 2014 | 1846 | 0.190 |
Why?
|
| Abdominal Fat | 2 | 2013 | 216 | 0.180 |
Why?
|
| Photosensitizing Agents | 2 | 2016 | 604 | 0.180 |
Why?
|
| Acute Coronary Syndrome | 4 | 2015 | 2334 | 0.180 |
Why?
|
| Liver Transplantation | 6 | 2013 | 2203 | 0.180 |
Why?
|
| Aged | 62 | 2020 | 164236 | 0.180 |
Why?
|
| Dibenzothiazepines | 2 | 2013 | 102 | 0.180 |
Why?
|
| Ventilators, Mechanical | 1 | 2002 | 284 | 0.180 |
Why?
|
| Drug Therapy, Combination | 12 | 2021 | 6459 | 0.180 |
Why?
|
| Bupropion | 3 | 2007 | 302 | 0.170 |
Why?
|
| Alzheimer Disease | 4 | 2019 | 8304 | 0.170 |
Why?
|
| Critical Care | 2 | 2014 | 2662 | 0.170 |
Why?
|
| Communicable Diseases | 2 | 2022 | 869 | 0.170 |
Why?
|
| HIV Wasting Syndrome | 4 | 2001 | 97 | 0.170 |
Why?
|
| Transplantation Tolerance | 3 | 2014 | 572 | 0.170 |
Why?
|
| Estrogens | 4 | 2021 | 1520 | 0.170 |
Why?
|
| Survival | 2 | 2017 | 159 | 0.170 |
Why?
|
| Schizophrenic Psychology | 4 | 2013 | 1635 | 0.170 |
Why?
|
| Placebo Effect | 1 | 2003 | 509 | 0.160 |
Why?
|
| Respiration, Artificial | 7 | 2019 | 2572 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2015 | 11940 | 0.160 |
Why?
|
| Placebos | 11 | 2012 | 1658 | 0.160 |
Why?
|
| Androgens | 4 | 2011 | 1275 | 0.160 |
Why?
|
| Estradiol | 6 | 2021 | 1941 | 0.160 |
Why?
|
| Kidney Transplantation | 6 | 2014 | 4091 | 0.160 |
Why?
|
| Statistics as Topic | 3 | 2003 | 2339 | 0.150 |
Why?
|
| Hand Strength | 4 | 2012 | 450 | 0.150 |
Why?
|
| Data Display | 1 | 2018 | 173 | 0.150 |
Why?
|
| Depressive Disorder, Major | 4 | 2020 | 4682 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2018 | 2244 | 0.150 |
Why?
|
| Breast Neoplasms | 3 | 2016 | 20750 | 0.150 |
Why?
|
| Quinidine | 1 | 2017 | 54 | 0.150 |
Why?
|
| Dextromethorphan | 1 | 2017 | 38 | 0.150 |
Why?
|
| Brain Edema | 1 | 2022 | 594 | 0.150 |
Why?
|
| Physical Endurance | 2 | 2017 | 360 | 0.150 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2022 | 342 | 0.150 |
Why?
|
| Substance Withdrawal Syndrome | 4 | 2017 | 625 | 0.150 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2018 | 3722 | 0.140 |
Why?
|
| Teriparatide | 1 | 1999 | 223 | 0.140 |
Why?
|
| Immunosuppressive Agents | 4 | 2018 | 4056 | 0.140 |
Why?
|
| Transplantation Conditioning | 3 | 2014 | 1568 | 0.140 |
Why?
|
| Blood Glucose | 9 | 2015 | 6213 | 0.140 |
Why?
|
| Models, Biological | 5 | 2019 | 9443 | 0.140 |
Why?
|
| Zidovudine | 3 | 1999 | 619 | 0.140 |
Why?
|
| Motor Neurons | 4 | 2009 | 850 | 0.140 |
Why?
|
| Androstenedione | 3 | 2001 | 131 | 0.140 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2016 | 41 | 0.140 |
Why?
|
| Blood Gas Analysis | 1 | 2017 | 377 | 0.140 |
Why?
|
| Statistics, Nonparametric | 3 | 2016 | 2841 | 0.140 |
Why?
|
| Graft Survival | 7 | 2014 | 3599 | 0.140 |
Why?
|
| Attention | 5 | 2019 | 2367 | 0.140 |
Why?
|
| Chimerism | 2 | 2014 | 152 | 0.130 |
Why?
|
| Hospital Mortality | 4 | 2019 | 5215 | 0.130 |
Why?
|
| Reproducibility of Results | 14 | 2019 | 19804 | 0.130 |
Why?
|
| Absorptiometry, Photon | 8 | 2021 | 1730 | 0.130 |
Why?
|
| Young Adult | 18 | 2021 | 57106 | 0.130 |
Why?
|
| Follow-Up Studies | 19 | 2019 | 38752 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2011 | 9116 | 0.130 |
Why?
|
| Parathyroid Hormone | 3 | 1999 | 1781 | 0.130 |
Why?
|
| Emergency Service, Hospital | 5 | 2017 | 7699 | 0.130 |
Why?
|
| Tissue Donors | 4 | 2014 | 2206 | 0.130 |
Why?
|
| BCG Vaccine | 2 | 2022 | 365 | 0.130 |
Why?
|
| Vital Capacity | 4 | 2019 | 952 | 0.130 |
Why?
|
| Remission, Spontaneous | 1 | 2015 | 383 | 0.130 |
Why?
|
| Tamoxifen | 1 | 2019 | 957 | 0.120 |
Why?
|
| Coma | 2 | 2022 | 483 | 0.120 |
Why?
|
| Muscle, Skeletal | 8 | 2012 | 4861 | 0.120 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2010 | 619 | 0.120 |
Why?
|
| Marijuana Abuse | 1 | 2019 | 404 | 0.120 |
Why?
|
| Ovary | 1 | 1999 | 961 | 0.120 |
Why?
|
| Appetite Depressants | 1 | 2015 | 108 | 0.120 |
Why?
|
| Exercise Therapy | 2 | 2017 | 904 | 0.120 |
Why?
|
| Monte Carlo Method | 3 | 2015 | 1266 | 0.120 |
Why?
|
| Administration, Cutaneous | 5 | 2021 | 705 | 0.120 |
Why?
|
| Tissue and Organ Procurement | 2 | 2013 | 889 | 0.120 |
Why?
|
| Singlet Oxygen | 1 | 2014 | 54 | 0.120 |
Why?
|
| Mecamylamine | 1 | 2013 | 27 | 0.120 |
Why?
|
| Hypogonadism | 6 | 2006 | 789 | 0.110 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2022 | 991 | 0.110 |
Why?
|
| Cryptogenic Organizing Pneumonia | 1 | 2013 | 28 | 0.110 |
Why?
|
| Coronary Angiography | 3 | 2015 | 4514 | 0.110 |
Why?
|
| Porphyrins | 1 | 2016 | 351 | 0.110 |
Why?
|
| Adolescent | 30 | 2021 | 86202 | 0.110 |
Why?
|
| Nicotinic Antagonists | 1 | 2013 | 94 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2003 | 663 | 0.110 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2013 | 58 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2015 | 20142 | 0.110 |
Why?
|
| Aminolevulinic Acid | 1 | 2014 | 139 | 0.110 |
Why?
|
| Appetite | 1 | 2015 | 248 | 0.110 |
Why?
|
| Anilides | 1 | 2016 | 406 | 0.110 |
Why?
|
| Reference Values | 12 | 2019 | 4875 | 0.110 |
Why?
|
| Time | 3 | 2020 | 540 | 0.100 |
Why?
|
| Tetrahydrofolates | 1 | 2012 | 58 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2002 | 1894 | 0.100 |
Why?
|
| Erythema | 1 | 2014 | 260 | 0.100 |
Why?
|
| Shock | 1 | 2015 | 316 | 0.100 |
Why?
|
| Benzodiazepines | 3 | 2015 | 1112 | 0.100 |
Why?
|
| Liposomes | 1 | 2016 | 778 | 0.100 |
Why?
|
| Single-Blind Method | 5 | 2022 | 1563 | 0.100 |
Why?
|
| Uric Acid | 1 | 2017 | 738 | 0.100 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2014 | 683 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 3 | 2014 | 2448 | 0.100 |
Why?
|
| Multiple Organ Failure | 1 | 2014 | 387 | 0.100 |
Why?
|
| Triage | 2 | 2023 | 958 | 0.100 |
Why?
|
| Hypopituitarism | 2 | 2006 | 247 | 0.100 |
Why?
|
| Polytetrafluoroethylene | 2 | 2011 | 236 | 0.100 |
Why?
|
| Etidronic Acid | 1 | 2011 | 63 | 0.100 |
Why?
|
| Follicular Phase | 4 | 1997 | 143 | 0.100 |
Why?
|
| Travel Medicine | 1 | 2011 | 81 | 0.100 |
Why?
|
| Patient Selection | 5 | 2019 | 4191 | 0.100 |
Why?
|
| Energy Intake | 3 | 2015 | 2114 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2019 | 10718 | 0.090 |
Why?
|
| Acute Disease | 5 | 2019 | 7116 | 0.090 |
Why?
|
| Oxytocin | 1 | 2015 | 397 | 0.090 |
Why?
|
| Fluoxetine | 1 | 2015 | 738 | 0.090 |
Why?
|
| Presenilins | 1 | 2011 | 53 | 0.090 |
Why?
|
| Photochemotherapy | 2 | 2015 | 807 | 0.090 |
Why?
|
| Fluid Therapy | 1 | 2015 | 585 | 0.090 |
Why?
|
| Fibrin | 1 | 2013 | 505 | 0.090 |
Why?
|
| Angina Pectoris | 1 | 2015 | 969 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2004 | 3820 | 0.090 |
Why?
|
| Vanadium | 1 | 2010 | 54 | 0.090 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2011 | 105 | 0.090 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2005 | 1367 | 0.090 |
Why?
|
| Bone Resorption | 3 | 2011 | 717 | 0.090 |
Why?
|
| Macaca fascicularis | 4 | 2014 | 904 | 0.090 |
Why?
|
| Albuterol | 1 | 2011 | 209 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2012 | 4296 | 0.090 |
Why?
|
| Adiposity | 2 | 2012 | 1822 | 0.090 |
Why?
|
| Outpatients | 2 | 2017 | 1551 | 0.090 |
Why?
|
| Obesity | 6 | 2013 | 12670 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 2019 | 1210 | 0.090 |
Why?
|
| Intention to Treat Analysis | 3 | 2020 | 414 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 3476 | 0.090 |
Why?
|
| Obesity, Abdominal | 1 | 2013 | 367 | 0.090 |
Why?
|
| Aluminum | 1 | 2010 | 152 | 0.090 |
Why?
|
| Sensitivity and Specificity | 7 | 2015 | 14537 | 0.090 |
Why?
|
| Troponin T | 1 | 2015 | 751 | 0.090 |
Why?
|
| Leuprolide | 2 | 2002 | 319 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 2 | 2014 | 2676 | 0.090 |
Why?
|
| Neoplasms | 3 | 2017 | 21688 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2015 | 1174 | 0.090 |
Why?
|
| Stem Cell Factor | 1 | 2010 | 197 | 0.090 |
Why?
|
| Insulin Infusion Systems | 1 | 2011 | 206 | 0.090 |
Why?
|
| Smoking | 2 | 2022 | 8975 | 0.080 |
Why?
|
| Computer Security | 1 | 2011 | 261 | 0.080 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2015 | 491 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2012 | 4335 | 0.080 |
Why?
|
| Growth Hormone | 4 | 2001 | 555 | 0.080 |
Why?
|
| End Stage Liver Disease | 1 | 2013 | 326 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2010 | 216 | 0.080 |
Why?
|
| Motivation | 1 | 2019 | 1963 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2019 | 23453 | 0.080 |
Why?
|
| Cross-Over Studies | 5 | 2017 | 2011 | 0.080 |
Why?
|
| Memory | 1 | 2018 | 2165 | 0.080 |
Why?
|
| Radioimmunoassay | 4 | 2004 | 871 | 0.080 |
Why?
|
| Hair | 2 | 2010 | 488 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2015 | 2667 | 0.080 |
Why?
|
| Observation | 1 | 2010 | 312 | 0.080 |
Why?
|
| Drug Monitoring | 1 | 2015 | 948 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2024 | 3172 | 0.080 |
Why?
|
| Pyridines | 2 | 2016 | 2841 | 0.080 |
Why?
|
| Body Mass Index | 8 | 2019 | 12633 | 0.080 |
Why?
|
| Magnesium | 2 | 2010 | 795 | 0.080 |
Why?
|
| Bone Remodeling | 2 | 2021 | 578 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2024 | 3327 | 0.080 |
Why?
|
| Hypothermia, Induced | 1 | 2013 | 751 | 0.080 |
Why?
|
| Anthropometry | 2 | 2012 | 1338 | 0.080 |
Why?
|
| Myocardial Infarction | 3 | 2015 | 11655 | 0.080 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2014 | 1338 | 0.080 |
Why?
|
| Retrospective Studies | 22 | 2022 | 78297 | 0.080 |
Why?
|
| Proteinuria | 1 | 2011 | 627 | 0.080 |
Why?
|
| Survivors | 3 | 2005 | 2302 | 0.080 |
Why?
|
| Regression Analysis | 8 | 2008 | 6332 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2003 | 2918 | 0.080 |
Why?
|
| Likelihood Functions | 3 | 2003 | 984 | 0.070 |
Why?
|
| Infusions, Intravenous | 6 | 2018 | 2206 | 0.070 |
Why?
|
| Acute Lung Injury | 1 | 2011 | 369 | 0.070 |
Why?
|
| Manganese | 1 | 2010 | 394 | 0.070 |
Why?
|
| Analysis of Variance | 6 | 2015 | 6220 | 0.070 |
Why?
|
| Treatment Failure | 4 | 2019 | 2614 | 0.070 |
Why?
|
| Benchmarking | 1 | 2014 | 1028 | 0.070 |
Why?
|
| Anxiety | 2 | 2019 | 4401 | 0.070 |
Why?
|
| Mastectomy | 1 | 2016 | 1816 | 0.070 |
Why?
|
| Hormones | 4 | 2006 | 873 | 0.070 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 2089 | 0.070 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2013 | 779 | 0.070 |
Why?
|
| Physical Examination | 1 | 2013 | 1232 | 0.070 |
Why?
|
| Blood Vessel Prosthesis | 2 | 2011 | 920 | 0.070 |
Why?
|
| Body Weight | 7 | 2012 | 4590 | 0.070 |
Why?
|
| Immunoconjugates | 1 | 2014 | 857 | 0.070 |
Why?
|
| Antiviral Agents | 4 | 2002 | 3012 | 0.070 |
Why?
|
| Apoptosis | 2 | 2014 | 9421 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2024 | 4271 | 0.070 |
Why?
|
| Immunologic Memory | 1 | 2013 | 1331 | 0.070 |
Why?
|
| Sulfonamides | 2 | 2007 | 1948 | 0.070 |
Why?
|
| Dietary Fats | 2 | 1994 | 1980 | 0.070 |
Why?
|
| Myography | 1 | 2007 | 110 | 0.070 |
Why?
|
| Muscles | 1 | 2011 | 1583 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 1135 | 0.070 |
Why?
|
| Dialysis | 2 | 2004 | 75 | 0.070 |
Why?
|
| Autoantibodies | 2 | 2012 | 2044 | 0.070 |
Why?
|
| Endocrine System Diseases | 1 | 2008 | 247 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1989 | 720 | 0.070 |
Why?
|
| Multivariate Analysis | 6 | 2019 | 12018 | 0.070 |
Why?
|
| Cardiovascular Diseases | 6 | 2013 | 15308 | 0.070 |
Why?
|
| Pituitary Neoplasms | 4 | 2001 | 1306 | 0.070 |
Why?
|
| Pyrazoles | 2 | 2007 | 1985 | 0.070 |
Why?
|
| Immunoglobulin G | 2 | 2014 | 4480 | 0.070 |
Why?
|
| Probability | 3 | 2016 | 2468 | 0.070 |
Why?
|
| Deoxyguanosine | 1 | 2006 | 86 | 0.060 |
Why?
|
| Travel | 1 | 2011 | 782 | 0.060 |
Why?
|
| Candidiasis | 2 | 1999 | 357 | 0.060 |
Why?
|
| Databases, Factual | 5 | 2017 | 7810 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2015 | 3423 | 0.060 |
Why?
|
| Vitamin D | 1 | 1999 | 3239 | 0.060 |
Why?
|
| Graft Rejection | 3 | 2014 | 4203 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2011 | 1188 | 0.060 |
Why?
|
| Thiazoles | 1 | 2012 | 1487 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2012 | 1868 | 0.060 |
Why?
|
| United States | 14 | 2019 | 70383 | 0.060 |
Why?
|
| Nicotine | 2 | 2007 | 671 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2014 | 7222 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 8511 | 0.060 |
Why?
|
| Electric Impedance | 2 | 2007 | 732 | 0.060 |
Why?
|
| Prognosis | 10 | 2017 | 29068 | 0.060 |
Why?
|
| Communicable Disease Control | 1 | 2011 | 841 | 0.060 |
Why?
|
| Risk Factors | 18 | 2019 | 72416 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1989 | 589 | 0.060 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2008 | 545 | 0.060 |
Why?
|
| Quality of Life | 6 | 2022 | 12984 | 0.060 |
Why?
|
| Luteal Phase | 2 | 1997 | 136 | 0.060 |
Why?
|
| Drug Administration Schedule | 5 | 2019 | 4858 | 0.060 |
Why?
|
| Therapeutics | 1 | 1984 | 114 | 0.060 |
Why?
|
| Trauma Severity Indices | 3 | 2014 | 478 | 0.060 |
Why?
|
| Adenoma | 4 | 2001 | 2138 | 0.060 |
Why?
|
| Neuropsychological Tests | 6 | 2013 | 6931 | 0.060 |
Why?
|
| Cognition | 5 | 2019 | 6773 | 0.060 |
Why?
|
| Arm | 2 | 2004 | 580 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2015 | 2836 | 0.060 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2009 | 774 | 0.060 |
Why?
|
| Liver Diseases | 2 | 2011 | 1268 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2014 | 2068 | 0.060 |
Why?
|
| Bone Density Conservation Agents | 1 | 2011 | 779 | 0.060 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2005 | 298 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2008 | 1679 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 1989 | 1229 | 0.060 |
Why?
|
| Intra-Abdominal Fat | 1 | 2008 | 580 | 0.060 |
Why?
|
| Leukocytes | 1 | 2011 | 2010 | 0.060 |
Why?
|
| Insulin | 4 | 2015 | 6470 | 0.060 |
Why?
|
| Prospective Studies | 14 | 2019 | 53218 | 0.060 |
Why?
|
| Coronary Vessels | 1 | 2015 | 3073 | 0.060 |
Why?
|
| Paget Disease, Extramammary | 1 | 2003 | 46 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 9105 | 0.060 |
Why?
|
| Drug Combinations | 2 | 2020 | 1958 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2002 | 1510 | 0.060 |
Why?
|
| Kinetics | 1 | 2011 | 6352 | 0.050 |
Why?
|
| Heart Arrest | 1 | 2013 | 1483 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2003 | 6637 | 0.050 |
Why?
|
| Tachycardia | 1 | 2005 | 602 | 0.050 |
Why?
|
| Renal Dialysis | 2 | 2011 | 1691 | 0.050 |
Why?
|
| Random Allocation | 2 | 2015 | 2385 | 0.050 |
Why?
|
| Ventricular Fibrillation | 1 | 2005 | 535 | 0.050 |
Why?
|
| Lung | 3 | 2015 | 9842 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2019 | 1162 | 0.050 |
Why?
|
| Cognition Disorders | 2 | 2008 | 3954 | 0.050 |
Why?
|
| Antidepressive Agents | 1 | 2015 | 2864 | 0.050 |
Why?
|
| Hospitalization | 1 | 2022 | 10329 | 0.050 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 13538 | 0.050 |
Why?
|
| Administration, Inhalation | 2 | 2018 | 1140 | 0.050 |
Why?
|
| Barotrauma | 1 | 2002 | 39 | 0.050 |
Why?
|
| Premenopause | 4 | 2013 | 1033 | 0.050 |
Why?
|
| Mathematics | 1 | 2003 | 716 | 0.050 |
Why?
|
| Clotrimazole | 2 | 1999 | 77 | 0.050 |
Why?
|
| Piperazines | 1 | 2012 | 2469 | 0.050 |
Why?
|
| Diabetes Mellitus | 3 | 2010 | 5764 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2013 | 4515 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2003 | 2584 | 0.050 |
Why?
|
| Drosophila melanogaster | 1 | 2011 | 1694 | 0.050 |
Why?
|
| Length of Stay | 5 | 2014 | 6292 | 0.050 |
Why?
|
| APACHE | 1 | 2002 | 267 | 0.050 |
Why?
|
| Facial Dermatoses | 1 | 2002 | 84 | 0.050 |
Why?
|
| Fluconazole | 2 | 1999 | 143 | 0.050 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2001 | 54 | 0.050 |
Why?
|
| Predictive Value of Tests | 6 | 2015 | 15009 | 0.050 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 2 | 1999 | 95 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2014 | 3782 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2015 | 5899 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 2887 | 0.050 |
Why?
|
| Diabetic Retinopathy | 1 | 2011 | 1246 | 0.050 |
Why?
|
| Acyclovir | 1 | 2002 | 266 | 0.050 |
Why?
|
| Ketoconazole | 1 | 2001 | 96 | 0.050 |
Why?
|
| Transplantation Chimera | 2 | 2014 | 604 | 0.050 |
Why?
|
| Age Factors | 5 | 2019 | 18146 | 0.050 |
Why?
|
| Delayed-Action Preparations | 4 | 2007 | 962 | 0.050 |
Why?
|
| Glucose Tolerance Test | 3 | 2013 | 1152 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 11064 | 0.050 |
Why?
|
| Airway Resistance | 1 | 2002 | 402 | 0.050 |
Why?
|
| Registries | 2 | 2015 | 8170 | 0.050 |
Why?
|
| Complement C4b | 1 | 2001 | 132 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 2254 | 0.050 |
Why?
|
| Clozapine | 2 | 2005 | 500 | 0.050 |
Why?
|
| Research | 1 | 2009 | 1951 | 0.050 |
Why?
|
| Cytomegalovirus Infections | 2 | 2002 | 823 | 0.050 |
Why?
|
| Animals | 20 | 2016 | 166331 | 0.050 |
Why?
|
| Recombinant Proteins | 4 | 2021 | 6508 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 2009 | 3695 | 0.050 |
Why?
|
| Withholding Treatment | 1 | 2004 | 602 | 0.040 |
Why?
|
| Virus Activation | 1 | 2002 | 316 | 0.040 |
Why?
|
| Waiting Lists | 3 | 2013 | 716 | 0.040 |
Why?
|
| beta 2-Microglobulin | 2 | 2001 | 315 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2006 | 742 | 0.040 |
Why?
|
| Circadian Rhythm | 2 | 2011 | 2532 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2007 | 1529 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 2 | 2013 | 916 | 0.040 |
Why?
|
| Demography | 3 | 2013 | 1629 | 0.040 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2001 | 237 | 0.040 |
Why?
|
| Diphosphonates | 2 | 2002 | 626 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2022 | 571 | 0.040 |
Why?
|
| Reaction Time | 2 | 2019 | 2063 | 0.040 |
Why?
|
| Calcium Gluconate | 1 | 1999 | 22 | 0.040 |
Why?
|
| Nafarelin | 1 | 1999 | 27 | 0.040 |
Why?
|
| Prescriptions | 1 | 2022 | 382 | 0.040 |
Why?
|
| Pentamidine | 1 | 1999 | 43 | 0.040 |
Why?
|
| Cryoglobulinemia | 1 | 2000 | 84 | 0.040 |
Why?
|
| Glioblastoma | 1 | 2015 | 3453 | 0.040 |
Why?
|
| Biocompatible Materials | 2 | 2011 | 1682 | 0.040 |
Why?
|
| Lumbar Vertebrae | 3 | 2021 | 1808 | 0.040 |
Why?
|
| Phosphates | 2 | 2002 | 761 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 5 | 2012 | 5982 | 0.040 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 1072 | 0.040 |
Why?
|
| Indans | 1 | 2000 | 92 | 0.040 |
Why?
|
| Gonadotropins | 2 | 1991 | 242 | 0.040 |
Why?
|
| Dapsone | 1 | 1999 | 57 | 0.040 |
Why?
|
| Internet | 1 | 2011 | 3037 | 0.040 |
Why?
|
| Didanosine | 1 | 1999 | 151 | 0.040 |
Why?
|
| Complement Activation | 1 | 2001 | 443 | 0.040 |
Why?
|
| Cardiomyopathies | 1 | 2011 | 1897 | 0.040 |
Why?
|
| Periodicity | 3 | 1997 | 348 | 0.040 |
Why?
|
| Tryptophan | 1 | 2001 | 477 | 0.040 |
Why?
|
| Huntington Disease | 1 | 2006 | 1133 | 0.040 |
Why?
|
| Incidence | 7 | 2019 | 20812 | 0.040 |
Why?
|
| Anticonvulsants | 2 | 2009 | 1867 | 0.040 |
Why?
|
| Herpes Simplex | 1 | 2002 | 470 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2019 | 260 | 0.040 |
Why?
|
| Calorimetry, Indirect | 2 | 2015 | 170 | 0.040 |
Why?
|
| Nootropic Agents | 1 | 2000 | 155 | 0.040 |
Why?
|
| Lymphokines | 1 | 2001 | 931 | 0.040 |
Why?
|
| Genome, Human | 1 | 2011 | 4356 | 0.040 |
Why?
|
| Transplantation, Homologous | 4 | 2014 | 4617 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 3011 | 0.040 |
Why?
|
| Clinical Protocols | 2 | 2015 | 1428 | 0.040 |
Why?
|
| Logistic Models | 4 | 2002 | 13164 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 1983 | 1337 | 0.040 |
Why?
|
| Acromegaly | 1 | 2001 | 304 | 0.040 |
Why?
|
| Polyamines | 1 | 1998 | 127 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 2001 | 781 | 0.040 |
Why?
|
| Tropicamide | 1 | 1997 | 22 | 0.040 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1999 | 243 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 7571 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2002 | 747 | 0.040 |
Why?
|
| Cocaine-Related Disorders | 1 | 2001 | 453 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2002 | 1354 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 4248 | 0.040 |
Why?
|
| Lung Injury | 1 | 2002 | 424 | 0.040 |
Why?
|
| Antifungal Agents | 2 | 1999 | 706 | 0.040 |
Why?
|
| Basal Metabolism | 1 | 1998 | 162 | 0.040 |
Why?
|
| Health Services Accessibility | 2 | 2013 | 5218 | 0.040 |
Why?
|
| Muromonab-CD3 | 1 | 1997 | 104 | 0.040 |
Why?
|
| Autoantigens | 1 | 2001 | 868 | 0.040 |
Why?
|
| Vascular Patency | 2 | 2011 | 889 | 0.040 |
Why?
|
| HIV Infections | 4 | 2005 | 16936 | 0.040 |
Why?
|
| Kidney Function Tests | 2 | 2014 | 664 | 0.040 |
Why?
|
| Half-Life | 2 | 2014 | 647 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2001 | 1809 | 0.040 |
Why?
|
| Inhibins | 1 | 1997 | 213 | 0.040 |
Why?
|
| Substance Abuse Detection | 1 | 2019 | 286 | 0.040 |
Why?
|
| Herpesvirus 1, Human | 1 | 2002 | 748 | 0.030 |
Why?
|
| Fish Oils | 2 | 2005 | 473 | 0.030 |
Why?
|
| Glycoproteins | 2 | 1996 | 2201 | 0.030 |
Why?
|
| Comorbidity | 3 | 2017 | 10351 | 0.030 |
Why?
|
| Insulin Resistance | 3 | 2006 | 3836 | 0.030 |
Why?
|
| Sodium Chloride | 1 | 2018 | 608 | 0.030 |
Why?
|
| Pupil | 1 | 1997 | 141 | 0.030 |
Why?
|
| Cushing Syndrome | 1 | 1998 | 242 | 0.030 |
Why?
|
| Recurrence | 4 | 2015 | 8373 | 0.030 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2001 | 710 | 0.030 |
Why?
|
| Cyclosporine | 1 | 1999 | 751 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2018 | 635 | 0.030 |
Why?
|
| Pilot Projects | 4 | 2018 | 8370 | 0.030 |
Why?
|
| Cell Count | 3 | 2007 | 1831 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1998 | 619 | 0.030 |
Why?
|
| Defibrillators, Implantable | 1 | 2005 | 1435 | 0.030 |
Why?
|
| Ovulation | 2 | 1997 | 180 | 0.030 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 1992 | 680 | 0.030 |
Why?
|
| Cross-Sectional Studies | 7 | 2015 | 25177 | 0.030 |
Why?
|
| Nerve Regeneration | 1 | 2001 | 781 | 0.030 |
Why?
|
| Immunoassay | 1 | 2019 | 731 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2019 | 964 | 0.030 |
Why?
|
| Hepatitis C, Chronic | 1 | 2004 | 1027 | 0.030 |
Why?
|
| Cocaine | 1 | 2001 | 982 | 0.030 |
Why?
|
| Milk | 1 | 1998 | 438 | 0.030 |
Why?
|
| Testicular Hormones | 1 | 1996 | 188 | 0.030 |
Why?
|
| Menstruation | 2 | 1998 | 306 | 0.030 |
Why?
|
| Child | 9 | 2011 | 78456 | 0.030 |
Why?
|
| Personality | 1 | 2019 | 542 | 0.030 |
Why?
|
| Gonadal Steroid Hormones | 4 | 2002 | 700 | 0.030 |
Why?
|
| Hydrocortisone | 2 | 2020 | 1776 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2011 | 11839 | 0.030 |
Why?
|
| Central Venous Pressure | 1 | 2015 | 77 | 0.030 |
Why?
|
| Drug Synergism | 3 | 2003 | 1731 | 0.030 |
Why?
|
| Cardiovascular System | 2 | 2013 | 830 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 6454 | 0.030 |
Why?
|
| Bone and Bones | 3 | 2002 | 2557 | 0.030 |
Why?
|
| Sumatriptan | 1 | 1995 | 65 | 0.030 |
Why?
|
| Sampling Studies | 2 | 1989 | 617 | 0.030 |
Why?
|
| Cholecystokinin | 1 | 2015 | 117 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 2 | 1993 | 1793 | 0.030 |
Why?
|
| Lung Compliance | 1 | 2015 | 196 | 0.030 |
Why?
|
| Growth Inhibitors | 1 | 1996 | 377 | 0.030 |
Why?
|
| Bone Diseases, Metabolic | 2 | 1988 | 409 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1997 | 576 | 0.030 |
Why?
|
| Prostatic Neoplasms | 3 | 2002 | 11216 | 0.030 |
Why?
|
| Safflower Oil | 1 | 1994 | 28 | 0.030 |
Why?
|
| ROC Curve | 2 | 2015 | 3496 | 0.030 |
Why?
|
| Furosemide | 1 | 2015 | 161 | 0.030 |
Why?
|
| Oximetry | 1 | 2017 | 458 | 0.030 |
Why?
|
| Capsaicin | 1 | 1995 | 226 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2002 | 1355 | 0.030 |
Why?
|
| Milk, Human | 1 | 1998 | 473 | 0.030 |
Why?
|
| Gyrus Cinguli | 1 | 2020 | 1101 | 0.030 |
Why?
|
| Thromboxane B2 | 1 | 1994 | 149 | 0.030 |
Why?
|
| Trigeminal Ganglion | 1 | 1995 | 187 | 0.030 |
Why?
|
| Life Tables | 2 | 2004 | 368 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2014 | 423 | 0.030 |
Why?
|
| Peer Group | 1 | 2019 | 649 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 1 | 2015 | 341 | 0.030 |
Why?
|
| Hemoglobins | 2 | 2015 | 1510 | 0.030 |
Why?
|
| AIDS-Related Complex | 1 | 1993 | 107 | 0.030 |
Why?
|
| Protoporphyrins | 1 | 2014 | 164 | 0.030 |
Why?
|
| Psychomotor Performance | 3 | 2007 | 1859 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2015 | 468 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 1993 | 1633 | 0.030 |
Why?
|
| Head | 1 | 1999 | 898 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2000 | 1146 | 0.030 |
Why?
|
| Hepatitis C | 2 | 2001 | 1588 | 0.030 |
Why?
|
| Database Management Systems | 1 | 2014 | 264 | 0.030 |
Why?
|
| Prolactin | 2 | 2001 | 627 | 0.030 |
Why?
|
| Receptors, Fc | 1 | 1996 | 527 | 0.030 |
Why?
|
| Pyrrolidines | 1 | 1995 | 333 | 0.030 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 1997 | 368 | 0.030 |
Why?
|
| Prednisone | 1 | 2018 | 1557 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2002 | 1415 | 0.030 |
Why?
|
| Blood Pressure | 4 | 2003 | 8404 | 0.030 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 1996 | 391 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2014 | 727 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 2015 | 17834 | 0.030 |
Why?
|
| Brain Injuries | 1 | 2004 | 2027 | 0.030 |
Why?
|
| Nervous System | 1 | 2016 | 540 | 0.030 |
Why?
|
| Software | 2 | 2009 | 4399 | 0.030 |
Why?
|
| Injections, Spinal | 1 | 2013 | 302 | 0.030 |
Why?
|
| Counseling | 1 | 2000 | 1522 | 0.030 |
Why?
|
| Injections, Subcutaneous | 2 | 2004 | 660 | 0.030 |
Why?
|
| Testis | 3 | 1996 | 792 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1995 | 571 | 0.030 |
Why?
|
| Age of Onset | 3 | 2009 | 3241 | 0.030 |
Why?
|
| Reward | 1 | 2018 | 932 | 0.020 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2012 | 148 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2001 | 1580 | 0.020 |
Why?
|
| Renin | 1 | 1994 | 637 | 0.020 |
Why?
|
| Mortality | 1 | 1983 | 2852 | 0.020 |
Why?
|
| Octreotide | 1 | 1992 | 149 | 0.020 |
Why?
|
| Diuretics | 1 | 2015 | 581 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 1999 | 972 | 0.020 |
Why?
|
| Threonine | 1 | 1992 | 273 | 0.020 |
Why?
|
| Pressure | 1 | 2015 | 1149 | 0.020 |
Why?
|
| Dioxanes | 1 | 1991 | 36 | 0.020 |
Why?
|
| Adrenal Insufficiency | 2 | 2006 | 190 | 0.020 |
Why?
|
| Muscle Spasticity | 1 | 1992 | 154 | 0.020 |
Why?
|
| Glutamate Decarboxylase | 1 | 2012 | 238 | 0.020 |
Why?
|
| Blood Specimen Collection | 2 | 1994 | 237 | 0.020 |
Why?
|
| Fasting | 1 | 1997 | 1575 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2017 | 1824 | 0.020 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2011 | 95 | 0.020 |
Why?
|
| Geography | 1 | 2013 | 653 | 0.020 |
Why?
|
| Piperidines | 1 | 2000 | 1634 | 0.020 |
Why?
|
| Inflammation | 2 | 2011 | 10592 | 0.020 |
Why?
|
| Growth Plate | 1 | 1993 | 271 | 0.020 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 1991 | 78 | 0.020 |
Why?
|
| Puberty, Precocious | 1 | 1992 | 162 | 0.020 |
Why?
|
| Models, Theoretical | 2 | 2008 | 3548 | 0.020 |
Why?
|
| Cell Division | 1 | 1998 | 4438 | 0.020 |
Why?
|
| Public Health Informatics | 1 | 2011 | 109 | 0.020 |
Why?
|
| Angiotensin II | 1 | 1994 | 867 | 0.020 |
Why?
|
| Muscle Contraction | 2 | 2007 | 1202 | 0.020 |
Why?
|
| Patient Compliance | 2 | 2017 | 2666 | 0.020 |
Why?
|
| C-Peptide | 1 | 2012 | 424 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 1994 | 788 | 0.020 |
Why?
|
| Proteins | 3 | 2006 | 6000 | 0.020 |
Why?
|
| Anti-HIV Agents | 3 | 2005 | 4406 | 0.020 |
Why?
|
| Personnel, Hospital | 1 | 1992 | 281 | 0.020 |
Why?
|
| Vaccination | 1 | 2022 | 3282 | 0.020 |
Why?
|
| Electrocardiography | 2 | 2015 | 6320 | 0.020 |
Why?
|
| Leukapheresis | 1 | 2010 | 129 | 0.020 |
Why?
|
| Calcium | 2 | 2002 | 5654 | 0.020 |
Why?
|
| Motor Skills | 2 | 2004 | 521 | 0.020 |
Why?
|
| Critical Illness | 2 | 2014 | 2690 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2014 | 2288 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 2372 | 0.020 |
Why?
|
| Mice | 8 | 2016 | 80087 | 0.020 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 1993 | 301 | 0.020 |
Why?
|
| Body Height | 2 | 2012 | 1554 | 0.020 |
Why?
|
| Exercise | 3 | 2001 | 5686 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2012 | 1015 | 0.020 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 57557 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1990 | 137 | 0.020 |
Why?
|
| Diagnosis, Differential | 3 | 2013 | 12839 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2013 | 755 | 0.020 |
Why?
|
| Cholesterol | 2 | 2000 | 2879 | 0.020 |
Why?
|
| Posture | 1 | 1994 | 949 | 0.020 |
Why?
|
| Carcinogenicity Tests | 1 | 1989 | 38 | 0.020 |
Why?
|
| Mitochondria | 2 | 2013 | 3523 | 0.020 |
Why?
|
| Ascitic Fluid | 1 | 1989 | 196 | 0.020 |
Why?
|
| Phenylacetates | 1 | 2009 | 114 | 0.020 |
Why?
|
| Intestines | 1 | 1998 | 1892 | 0.020 |
Why?
|
| Public Health Administration | 1 | 2011 | 242 | 0.020 |
Why?
|
| Endotoxins | 1 | 2011 | 524 | 0.020 |
Why?
|
| Growth Disorders | 1 | 1994 | 623 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1993 | 790 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2001 | 2193 | 0.020 |
Why?
|
| Ganciclovir | 1 | 1989 | 253 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2012 | 690 | 0.020 |
Why?
|
| Skinfold Thickness | 1 | 2008 | 158 | 0.020 |
Why?
|
| Body Surface Area | 2 | 2002 | 196 | 0.020 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2008 | 43 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2001 | 5032 | 0.020 |
Why?
|
| Amino Acids | 3 | 2001 | 1702 | 0.020 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2010 | 252 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2019 | 5092 | 0.020 |
Why?
|
| Silicones | 1 | 1989 | 228 | 0.020 |
Why?
|
| Osteocalcin | 2 | 2001 | 270 | 0.020 |
Why?
|
| Splenectomy | 1 | 2010 | 388 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 689 | 0.020 |
Why?
|
| Spine | 2 | 2011 | 1092 | 0.020 |
Why?
|
| Oligopeptides | 1 | 1994 | 1187 | 0.020 |
Why?
|
| Action Potentials | 2 | 2007 | 1772 | 0.020 |
Why?
|
| CD40 Ligand | 1 | 2010 | 487 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2001 | 3716 | 0.020 |
Why?
|
| Age Distribution | 1 | 2014 | 2842 | 0.020 |
Why?
|
| Skin | 2 | 2014 | 4390 | 0.020 |
Why?
|
| Pancreatitis | 1 | 1995 | 1098 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 1781 | 0.020 |
Why?
|
| Artificial Organs | 1 | 1989 | 149 | 0.020 |
Why?
|
| C-Reactive Protein | 2 | 2013 | 3751 | 0.020 |
Why?
|
| Viral Load | 3 | 2004 | 3297 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2001 | 3032 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 3526 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 16657 | 0.020 |
Why?
|
| Review Literature as Topic | 1 | 2009 | 326 | 0.020 |
Why?
|
| Brain | 3 | 2018 | 26596 | 0.020 |
Why?
|
| Computer Graphics | 1 | 2009 | 347 | 0.020 |
Why?
|
| Calcium Channels | 1 | 2011 | 617 | 0.020 |
Why?
|
| Menstrual Cycle | 3 | 2001 | 535 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2001 | 3061 | 0.020 |
Why?
|
| Eating | 1 | 1994 | 1531 | 0.020 |
Why?
|
| Minerals | 1 | 1988 | 279 | 0.020 |
Why?
|
| Prevalence | 4 | 2013 | 15308 | 0.020 |
Why?
|
| Hepatitis B | 1 | 1992 | 692 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2012 | 1065 | 0.020 |
Why?
|
| Child, Preschool | 4 | 2011 | 41376 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2011 | 722 | 0.020 |
Why?
|
| Computers | 1 | 2009 | 590 | 0.020 |
Why?
|
| Hypothalamus | 1 | 1992 | 992 | 0.020 |
Why?
|
| Dyspnea | 1 | 2014 | 1308 | 0.020 |
Why?
|
| Case-Control Studies | 4 | 2012 | 21673 | 0.020 |
Why?
|
| Islets of Langerhans | 2 | 2004 | 1321 | 0.020 |
Why?
|
| Progesterone | 3 | 1997 | 744 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2015 | 1952 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2011 | 1540 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 3669 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2009 | 933 | 0.020 |
Why?
|
| Health Resources | 1 | 2012 | 906 | 0.020 |
Why?
|
| Biopsy | 2 | 2013 | 6732 | 0.020 |
Why?
|
| Administration, Oral | 3 | 2001 | 3966 | 0.020 |
Why?
|
| Affect | 2 | 2006 | 1459 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2013 | 2412 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2012 | 3581 | 0.020 |
Why?
|
| Boston | 3 | 2005 | 9209 | 0.020 |
Why?
|
| Biological Availability | 1 | 2006 | 394 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2013 | 3133 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2008 | 905 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 1476 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2011 | 1404 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2012 | 2258 | 0.020 |
Why?
|
| Insulin-Secreting Cells | 1 | 2012 | 892 | 0.020 |
Why?
|
| Mutation | 2 | 2001 | 29614 | 0.020 |
Why?
|
| Plant Oils | 1 | 2005 | 197 | 0.020 |
Why?
|
| Linear Models | 1 | 2015 | 5821 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2013 | 2215 | 0.020 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2004 | 48 | 0.020 |
Why?
|
| Amenorrhea | 1 | 1988 | 497 | 0.010 |
Why?
|
| Histone Deacetylases | 1 | 2009 | 706 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 2070 | 0.010 |
Why?
|
| Autoimmunity | 1 | 2012 | 1332 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2014 | 5835 | 0.010 |
Why?
|
| Carbon Monoxide | 1 | 2007 | 540 | 0.010 |
Why?
|
| Hospitals, General | 2 | 2002 | 761 | 0.010 |
Why?
|
| Electrodiagnosis | 1 | 2004 | 148 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 3642 | 0.010 |
Why?
|
| Kidney | 1 | 1999 | 6982 | 0.010 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2004 | 186 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2011 | 5048 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2012 | 2461 | 0.010 |
Why?
|
| Dinoprostone | 1 | 2006 | 596 | 0.010 |
Why?
|
| Psychometrics | 1 | 2012 | 2993 | 0.010 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2008 | 740 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 2004 | 572 | 0.010 |
Why?
|
| Oxygen | 1 | 2015 | 4175 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1994 | 2478 | 0.010 |
Why?
|
| Pattern Recognition, Automated | 1 | 2009 | 990 | 0.010 |
Why?
|
| Nutrition Assessment | 1 | 2006 | 715 | 0.010 |
Why?
|
| Femur | 2 | 2001 | 1287 | 0.010 |
Why?
|
| Risk | 1 | 2015 | 9520 | 0.010 |
Why?
|
| Glycine | 2 | 1999 | 656 | 0.010 |
Why?
|
| Radiography | 1 | 2013 | 6939 | 0.010 |
Why?
|
| Goserelin | 1 | 2003 | 127 | 0.010 |
Why?
|
| Risperidone | 1 | 2005 | 380 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 6420 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 2007 | 1727 | 0.010 |
Why?
|
| Chondroitin Sulfates | 1 | 2002 | 175 | 0.010 |
Why?
|
| Body Size | 1 | 2005 | 458 | 0.010 |
Why?
|
| Cholesterol, HDL | 2 | 2000 | 1795 | 0.010 |
Why?
|
| Androsterone | 1 | 2001 | 14 | 0.010 |
Why?
|
| Etiocholanolone | 1 | 2001 | 7 | 0.010 |
Why?
|
| Blood-Brain Barrier | 1 | 2008 | 1007 | 0.010 |
Why?
|
| Glucuronides | 1 | 2001 | 20 | 0.010 |
Why?
|
| Depression | 2 | 2019 | 7826 | 0.010 |
Why?
|
| Burn Units | 1 | 2002 | 139 | 0.010 |
Why?
|
| Quality Control | 1 | 2004 | 819 | 0.010 |
Why?
|
| Complement C5b | 1 | 2001 | 9 | 0.010 |
Why?
|
| Electromyography | 1 | 2007 | 1374 | 0.010 |
Why?
|
| Drosophila Proteins | 1 | 2011 | 1693 | 0.010 |
Why?
|
| Cohort Studies | 3 | 2015 | 40503 | 0.010 |
Why?
|
| Electrophysiology | 1 | 2004 | 1267 | 0.010 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2006 | 709 | 0.010 |
Why?
|
| Freund's Adjuvant | 1 | 2001 | 149 | 0.010 |
Why?
|
| Body Temperature | 1 | 2004 | 767 | 0.010 |
Why?
|
| Crohn Disease | 1 | 1994 | 2243 | 0.010 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2004 | 543 | 0.010 |
Why?
|
| Complement C5 | 1 | 2001 | 105 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2011 | 2188 | 0.010 |
Why?
|
| H-2 Antigens | 1 | 2001 | 357 | 0.010 |
Why?
|
| Dihydrotestosterone | 1 | 2001 | 194 | 0.010 |
Why?
|
| Sex Factors | 2 | 2012 | 10279 | 0.010 |
Why?
|
| Organic Chemicals | 1 | 2001 | 209 | 0.010 |
Why?
|
| Complement C4 | 1 | 2001 | 244 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2004 | 1580 | 0.010 |
Why?
|
| Reference Standards | 1 | 2004 | 1001 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2004 | 1132 | 0.010 |
Why?
|
| Lipids | 2 | 2005 | 3290 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 2012 | 10018 | 0.010 |
Why?
|
| Cattle | 2 | 1998 | 3840 | 0.010 |
Why?
|
| Arousal | 1 | 2006 | 1146 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 751 | 0.010 |
Why?
|
| Weight Lifting | 1 | 2000 | 123 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 2001 | 387 | 0.010 |
Why?
|
| Nutritional Status | 2 | 1998 | 1578 | 0.010 |
Why?
|
| Leptin | 2 | 1998 | 1579 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2011 | 3017 | 0.010 |
Why?
|
| Pelvic Bones | 1 | 2001 | 269 | 0.010 |
Why?
|
| Cell Transplantation | 1 | 2001 | 470 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2004 | 1349 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 674 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2000 | 549 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2012 | 3186 | 0.010 |
Why?
|
| Genotype | 1 | 2013 | 12773 | 0.010 |
Why?
|
| Estrone | 1 | 2000 | 233 | 0.010 |
Why?
|
| Eflornithine | 1 | 1998 | 31 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 6453 | 0.010 |
Why?
|
| Spermidine | 1 | 1998 | 60 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 2001 | 788 | 0.010 |
Why?
|
| 17-Hydroxycorticosteroids | 1 | 1998 | 39 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 1146 | 0.010 |
Why?
|
| Heart Rate | 2 | 2003 | 4039 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2000 | 299 | 0.010 |
Why?
|
| Observer Variation | 1 | 2004 | 2574 | 0.010 |
Why?
|
| Calcium, Dietary | 1 | 2001 | 515 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2000 | 519 | 0.010 |
Why?
|
| Tomography, Optical Coherence | 1 | 2011 | 2805 | 0.010 |
Why?
|
| Tritium | 1 | 1998 | 708 | 0.010 |
Why?
|
| Infant Food | 1 | 1998 | 141 | 0.010 |
Why?
|
| Weight Gain | 2 | 1998 | 2310 | 0.010 |
Why?
|
| Behavior | 1 | 2001 | 546 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 35784 | 0.010 |
Why?
|
| Pulsatile Flow | 1 | 1999 | 316 | 0.010 |
Why?
|
| Infant | 3 | 2011 | 35444 | 0.010 |
Why?
|
| Ovarian Neoplasms | 2 | 1996 | 4845 | 0.010 |
Why?
|
| Multiple Sclerosis | 1 | 1992 | 3132 | 0.010 |
Why?
|
| Valproic Acid | 1 | 2000 | 441 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1993 | 6453 | 0.010 |
Why?
|
| Hirsutism | 1 | 1997 | 68 | 0.010 |
Why?
|
| Cost of Illness | 2 | 2000 | 1878 | 0.010 |
Why?
|
| Electroencephalography | 1 | 2012 | 6072 | 0.010 |
Why?
|
| Computational Biology | 1 | 2009 | 3484 | 0.010 |
Why?
|
| Secretory Rate | 1 | 1996 | 82 | 0.010 |
Why?
|
| Mice, Transgenic | 2 | 2001 | 9441 | 0.010 |
Why?
|
| Lipoproteins | 1 | 2002 | 881 | 0.010 |
Why?
|
| Thromboembolism | 1 | 2003 | 1003 | 0.010 |
Why?
|
| Hypertriglyceridemia | 1 | 2000 | 308 | 0.010 |
Why?
|
| Physical Fitness | 1 | 2001 | 723 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1996 | 306 | 0.010 |
Why?
|
| Aspirin | 1 | 2008 | 3286 | 0.010 |
Why?
|
| Pancreatectomy | 1 | 2001 | 808 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1996 | 363 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 2006 | 2045 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1998 | 2193 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 8355 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 1996 | 67 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 1998 | 635 | 0.010 |
Why?
|
| Osteogenesis | 1 | 2003 | 1257 | 0.010 |
Why?
|
| Environmental Exposure | 1 | 2010 | 4315 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2000 | 1601 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2001 | 1239 | 0.010 |
Why?
|
| Prediabetic State | 1 | 2001 | 523 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 851 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2001 | 1032 | 0.010 |
Why?
|
| Remission Induction | 1 | 2001 | 2361 | 0.010 |
Why?
|
| Granulosa Cells | 1 | 1996 | 118 | 0.010 |
Why?
|
| Rats | 3 | 1998 | 23680 | 0.010 |
Why?
|
| Massachusetts | 2 | 2002 | 8593 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1995 | 184 | 0.010 |
Why?
|
| Hemophilia A | 1 | 1998 | 354 | 0.010 |
Why?
|
| Amylases | 1 | 1995 | 170 | 0.010 |
Why?
|
| Leg | 1 | 2000 | 1086 | 0.010 |
Why?
|
| Smoke Inhalation Injury | 1 | 1995 | 48 | 0.010 |
Why?
|
| Cisterna Magna | 1 | 1995 | 40 | 0.010 |
Why?
|
| Dimerization | 1 | 1997 | 886 | 0.010 |
Why?
|
| Pancreatic Pseudocyst | 1 | 1995 | 109 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2004 | 21529 | 0.010 |
Why?
|
| Disorders of Sex Development | 1 | 1996 | 129 | 0.010 |
Why?
|
| Calcitriol | 1 | 1996 | 294 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2001 | 1318 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2004 | 3153 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2004 | 2923 | 0.010 |
Why?
|
| Collagen | 1 | 2002 | 2618 | 0.010 |
Why?
|
| Receptors, LHRH | 1 | 1994 | 158 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 1996 | 414 | 0.010 |
Why?
|
| Immunotherapy | 1 | 1989 | 4594 | 0.010 |
Why?
|
| Ovariectomy | 1 | 1996 | 610 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2004 | 1612 | 0.010 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1999 | 880 | 0.010 |
Why?
|
| Anti-Mullerian Hormone | 1 | 1996 | 401 | 0.010 |
Why?
|
| Bone Development | 1 | 1996 | 472 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1995 | 1315 | 0.010 |
Why?
|
| Lipase | 1 | 1995 | 311 | 0.010 |
Why?
|
| Pancreatic Diseases | 1 | 1995 | 344 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1994 | 664 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1996 | 1028 | 0.010 |
Why?
|
| Hepatitis A Antibodies | 1 | 1992 | 20 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1999 | 1599 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2005 | 3324 | 0.010 |
Why?
|
| Hepatitis Antibodies | 1 | 1992 | 69 | 0.010 |
Why?
|
| Puberty | 1 | 1996 | 490 | 0.010 |
Why?
|
| Multiple Trauma | 1 | 1995 | 371 | 0.010 |
Why?
|
| Urine | 1 | 1994 | 354 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1999 | 3426 | 0.010 |
Why?
|
| Hepatitis B Core Antigens | 1 | 1992 | 89 | 0.010 |
Why?
|
| Triglycerides | 1 | 2000 | 2432 | 0.010 |
Why?
|
| Testolactone | 1 | 1991 | 5 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2001 | 2117 | 0.010 |
Why?
|
| Neutrophils | 1 | 2004 | 3706 | 0.010 |
Why?
|
| DNA | 2 | 1998 | 7199 | 0.010 |
Why?
|
| Idazoxan | 1 | 1991 | 9 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2002 | 2511 | 0.010 |
Why?
|
| Injections | 1 | 1995 | 830 | 0.010 |
Why?
|
| Postmenopause | 1 | 2001 | 2461 | 0.010 |
Why?
|
| Abscess | 1 | 1995 | 600 | 0.010 |
Why?
|
| Cell Survival | 1 | 2001 | 5761 | 0.010 |
Why?
|
| Motor Activity | 1 | 2001 | 2666 | 0.010 |
Why?
|
| Vitamin D Deficiency | 1 | 2001 | 1356 | 0.010 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1992 | 298 | 0.010 |
Why?
|
| Nociceptors | 1 | 1995 | 449 | 0.010 |
Why?
|
| Ferritins | 1 | 1994 | 583 | 0.010 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1991 | 172 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 1992 | 387 | 0.010 |
Why?
|
| Respiratory Mechanics | 1 | 1995 | 680 | 0.010 |
Why?
|
| Cryopreservation | 1 | 1996 | 700 | 0.010 |
Why?
|
| DNA, Single-Stranded | 1 | 1993 | 358 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1994 | 17675 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1998 | 1919 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2001 | 3460 | 0.010 |
Why?
|
| Somatostatin | 1 | 1992 | 443 | 0.010 |
Why?
|
| Exercise Test | 1 | 1998 | 2082 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2002 | 3258 | 0.010 |
Why?
|
| Osteoblasts | 1 | 1996 | 1137 | 0.010 |
Why?
|
| Sepsis | 1 | 2004 | 2589 | 0.010 |
Why?
|
| Disabled Persons | 1 | 2000 | 1191 | 0.010 |
Why?
|
| Zinc | 1 | 1994 | 683 | 0.010 |
Why?
|
| Fatty Acids | 1 | 1997 | 1777 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1993 | 854 | 0.010 |
Why?
|
| Silicone Elastomers | 1 | 1989 | 79 | 0.010 |
Why?
|
| Proteoglycans | 1 | 1993 | 802 | 0.010 |
Why?
|
| Menarche | 1 | 1992 | 527 | 0.010 |
Why?
|
| Immunologic Tests | 1 | 1990 | 102 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1989 | 406 | 0.010 |
Why?
|
| Family | 1 | 2000 | 3156 | 0.010 |
Why?
|
| Aldosterone | 1 | 1994 | 861 | 0.010 |
Why?
|
| Weight Loss | 1 | 2000 | 2636 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 1995 | 1050 | 0.010 |
Why?
|
| Chronobiology Phenomena | 1 | 1988 | 29 | 0.000 |
Why?
|
| Feedback | 1 | 1991 | 780 | 0.000 |
Why?
|
| Mitosis | 1 | 1993 | 1190 | 0.000 |
Why?
|
| Hyperprolactinemia | 1 | 1988 | 126 | 0.000 |
Why?
|
| Hypothalamic Diseases | 1 | 1988 | 134 | 0.000 |
Why?
|
| Bacterial Infections | 1 | 1995 | 1395 | 0.000 |
Why?
|
| Pituitary Gland | 1 | 1989 | 634 | 0.000 |
Why?
|
| Forecasting | 1 | 1995 | 2905 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 2001 | 14211 | 0.000 |
Why?
|
| Visual Fields | 1 | 1992 | 1038 | 0.000 |
Why?
|
| Gait | 1 | 1991 | 799 | 0.000 |
Why?
|
| Thyrotropin | 1 | 1989 | 830 | 0.000 |
Why?
|
| Patient Satisfaction | 1 | 1998 | 3408 | 0.000 |
Why?
|
| Iron | 1 | 1994 | 1735 | 0.000 |
Why?
|
| Mental Health | 1 | 2000 | 3091 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1989 | 2466 | 0.000 |
Why?
|
| Psychotic Disorders | 1 | 2000 | 3100 | 0.000 |
Why?
|
| Radionuclide Imaging | 1 | 1988 | 1978 | 0.000 |
Why?
|
| Movement | 1 | 1991 | 1464 | 0.000 |
Why?
|
| Cell Line | 1 | 1998 | 15631 | 0.000 |
Why?
|
| Activities of Daily Living | 1 | 1993 | 2379 | 0.000 |
Why?
|
| Skin Transplantation | 1 | 1989 | 1022 | 0.000 |
Why?
|
| Medical Records | 1 | 1989 | 1390 | 0.000 |
Why?
|
| Radiographic Image Enhancement | 1 | 1988 | 868 | 0.000 |
Why?
|
| Endoscopy | 1 | 1993 | 1829 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 6058 | 0.000 |
Why?
|
| Diet | 1 | 2001 | 7881 | 0.000 |
Why?
|
| Homeostasis | 1 | 1994 | 3260 | 0.000 |
Why?
|
| Carrier Proteins | 1 | 1996 | 4926 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 13494 | 0.000 |
Why?
|
| Menopause | 1 | 1990 | 1615 | 0.000 |
Why?
|
| Population Surveillance | 1 | 1992 | 2586 | 0.000 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1993 | 8125 | 0.000 |
Why?
|
| Base Sequence | 1 | 1993 | 12447 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 1995 | 11036 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 11539 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1989 | 6095 | 0.000 |
Why?
|
| Gene Expression | 1 | 1993 | 7580 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 2001 | 8832 | 0.000 |
Why?
|
| HIV-1 | 1 | 1997 | 6870 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2000 | 17434 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1993 | 12741 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1993 | 18891 | 0.000 |
Why?
|
| Dementia | 1 | 1991 | 2545 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1996 | 25752 | 0.000 |
Why?
|
| Pregnancy | 1 | 1997 | 29294 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1993 | 15341 | 0.000 |
Why?
|